CCR 20th anniversary commentary: a chimeric antibody, C225, inhibits EGFR activation and tumor growth

John Mendelsohn1, Marie Prewett2, Patricia Rockwell3

  • 1The University of Texas MD Anderson Cancer Center, Houston, Texas. jmendelsohn@mdanderson.org.